STAT3 and melanoma: In summary (Fig. 6), we conclude that CIRT can reduce the population of MDSC through a JAK2/STAT3-dependent signalling pathway, boost anti-tumour immune responses, and reduce tumour growth, therefore, increasing the overall survival of the melanoma-bearing mice.